Current Report Filing (8-k)
March 15 2017 - 5:27PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange
Act of 1934
Date of Report (Date of earliest event reported):
March 15,
2017
BIOSPECIFICS TECHNOLOGIES CORP.
(Exact name of
registrant as specified in its charter)
Delaware
|
001-34236
|
11-3054851
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
of incorporation)
|
File Number)
|
Identification No.)
|
35 Wilbur Street
|
11563
|
Lynbrook, NY
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrants telephone number, including area code:
516.593.7000
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e -4(c))
Introductory Comment
Throughout this Current Report on Form 8-K, the terms we,
us, our and Company refer to BioSpecifics Technologies Corp.
Item 2.02.
|
Results of Operations and Financial
Condition
|
On March 15, 2017, the Company announced its financial and
operating results for the fiscal quarter and full year ended December 31, 2016.
The full text of the press release issued in connection with the announcement is
attached as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with General Instruction B.2 of Form 8-K, the
information in this Current Report on Form 8-K, including Exhibit 99.1, shall
not be deemed to be filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific reference in
such filing
Item 9.01.
|
Financial Statements and Exhibits
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: March 15, 2017
BioSpecifics Technologies Corp.
By:
/s/ Carl Valenstein
Name: Carl Valenstein
Title: Secretary
EXHIBIT INDEX
BioSpecifics Technologies (NASDAQ:BSTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSpecifics Technologies (NASDAQ:BSTC)
Historical Stock Chart
From Apr 2023 to Apr 2024